Arranta Bio
Biologics / Microbiome / mRNA-Based Development & Manufacturing – CDMO
Goals & Objectives
Arranta Bio was a CDMO founded in 2019 to focus on microbiome-based therapeutics. It was formed by a strategic acquisition of an experienced microbiome-focused company called Captozyme and wanted to establish Arranta as a brand positioned to become the go-to CDMO in that niche segment.
Strategic Approach
When Arranta launched, microbiome-based therapies were rekindling interest after decades of being largely ignored in the antibiotic era. We employed thought leadership content to build an audience for both the microbiome therapeutic concept and Arranta being positioned as its pioneering CDMO.
Meeting & Exceeding KPIs
Poor subsequent clinical trial results in the space dented confidence, so Arranta pivoted to focus on plasmids and the growth in interest in mRNA vaccines and therapeutics. With private equity partners, a $200M facility expansion in Boston was funded, and Recipharm acquired Arranta Bio for $700M in late 2022.
